- Jazz Pharmaceuticals (NASDAQ:JAZZ) is down 7% after hours on light volume on the heels of the company's announcement that enrollment is now complete in its 240-subject Phase 3 clinical trial assessing JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy. Top-line data are expected in Q2 2017.
- Top-line results in another Phase 3 assessing JZP-110 for the treatment of ES in obstructive sleep apnea should be available in Q1 2017.
- JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor. It has Orphan Drug status in the U.S. for narcolepsy.